Scientific breakthrough in skin ageing from Vichy

London:A new scientific discovery, the fruit of 10 years research into understanding skin ageing, has resulted in the creation of a new generation cream.

Vichy LiftActiv Derm Source the skin cream that has been dubbed by the press as a ‘wrinkle cream first’ targeting the skin’s ageing process went on sale in Britain last week, following a wave of media and consumer interest in the product ever since scientific research on its breakthrough formulation was revealed at the beginning of the year.

femme_liftactiv.jpgThe breakthrough, backed by rigorous scientific testing and independent analysis, with the findings published in various medical journals such as PLoS ONE*, has seen scientists identify the key role of papillary fibroblasts in the Derm Source (also known as the papillary dermis), in the production of collagen fibres which keep the skin plump and elastic.

Taking its lead from the expert and scientific methodologies used in the pharmaceutical industry, researcher’s trialled 50 different compounds to identify the most effective ingredient to specifically target the Derm Source and actively stimulate the production of collagen fibres and through this testing, identified Rhamnose, a derivative of the Silver Birch Tree and Cat’s Claw (Uncaria) as the clear winner.

The product containing this active ingredient is called LiftActiv Derm Source by Vichy. It has been tested on 800 women, 40% of which have sensitive skin and there have been 6 clinical tests carried out plus 2 in vivo studies.

Dermatologists found a measurable decrease in the five leading types of wrinkles in the areas tested (face and neck).

Watch our video below to see how the product works and how the experts predict it will revolutionise the skin care industry.


Enhanced by Zemanta

Intercytex to bring potent facial rejuvenator to market this year


London: The British biotech company Intercytex (ICX.L) with a market capitalisation of $98m (£50m, €76m) which floated on the UK’s Alternative Investment Market earlier this year, has an attractive pipeline of products within the anti-ageing and rejuvenation sector – all based on cell culture.

Last year it secured a UK government investment of $3.72m (£1.9m, €2.87m) to develop a baldness cure by growing hair follicles for transplant. But it will be a while before this product comes to market, particularly since it needs the approval of the government’s Medicines & Healthcare Regulatory Agency (MHRA). It is also growing human skin for the treatment of burns and other serious medical conditions such as ulcers.

But the most interesting product which the company is already talking to cosmetic surgeons about is the world’s first anti-ageing skin rejuvenation injection made from human baby foreskins. These are the most potent skin cells it is so far possible to “harvest” – promising that the treatment will be far more effective than any other to date. And don’t be deceived into believing that the “yuk” factor will put women (and even men) off trying it. A skin cream containing cells from a similar source has become a best seller in the US.

What is different about this treatment is that the cells are “immune silent” which means they can be injected into anyone without allergic or immune reactions. They do not need the expensive individual storage conditions required for own cells.

This makes the cost of bringing the treatment to market cheaper and it will cost only a few hundred pounds compared to the only similar product Isolagen, which used a person’s own cells and was charging £4,500 in the UK because of expensive storage and was forced to close its operation last year.

In addition the raw material is free from the US where hospitals are forbidden to sell body parts and the process requires only one foreskin each year – grow millions of cells to treat many thousands of patients

After positive results from efficacy tests on arms, the company now undertaking facial trials before treating its first consumers.

The global market for anti-ageing products and services is estimated at US $56 billion worldwide (£29.7bn, €43bn) so the potential for this product is enormous.

At the moment Intercytex’ share price its languishing below its float price at around £1.08 p so it would seem sensible to get in early like the institutions Framlington (5%) Foreign & Colonial (3%) Avlar (25%). BUY